|CANCER & TREATMENTS FOR CANCER CENTER PATIENTS PREVENTION & RISK ASSESSMENT CLINICAL TRIALS & RESEARCH LIVING WITH CANCER|
Please note: This article is part of the Cancer Center's News Archive and is here for historical purposes. The information and links may no longer be up-to-date.
Michigan Oncology Journal Spring 98
ProstaScint Scanning Now Available at U-M
ProstaScint scanning is useful for locating the source of a rising serum prostate specific antigen (PSA) level in patients who are post-radical prostatectomy and who have had negative or equivocal tests to localize the site of recurrence. With the information provided by the scan, in concert with other information, management of these patients may be made more appropriate. An article in Januarys Journal of Clinical Oncology showed that patients who have rising PSA levels and a ProstaScint scan that shows no distant metastases are much more likely to benefit from radiation therapy to the pelvis than patients whose scans show disseminated disease. Although based on a small sample size, the results were highly significant, says Richard Wahl, M.D., director of U-Ms General Nuclear Imaging.
Medicare Now Covers Positron Imaging with FDG for Lung Cancer
Richard L. Wahl, M.D., professor of Internal Medicine and Radiology and director of the Cancer Centers Radiopharmaceutical Program, participated in the Health Care Financing Organizations development of these guidelines. In 1994, he along with colleagues Leslie Quint, Mark Orringer and Charles Meyer were first to report that PET was significantly more accurate than CT scanning in staging non-small cell lung cancer. These results have been confirmed by multiple other groups in the past several years, and Blue Cross/Blue Shield Association Technical Evaluation Center recently concluded that PET with FDG is clinically effective and can improve health outcomes in patients with lung cancer. Because PET is more accurate than CT, it can lead to more appropriate management at a lower overall cost.
The U-Ms Division of Nuclear Medicine offers clinical
PET studies on a routine basis. To schedule PET scans, please
call (734) 936-5090.
Randomized trial is comparing dose-escalated external
beam conformal boost versus brachytherapy boost in patients
with localized intermediate risk adenocarcinoma of the prostate.
The C.A.R.E Project (Cervical Application of Retinoid
Evaluation) is seeking patients with confirmed high-grade
cervial lesions (CIN II and III).
The University of Michigan Cancer Center is soliciting
concepts or full protocols for clinical trials to improve
cancer prevention and control practices in community clinical